Get the Stockscreener App
4.80
2.43%
0.12
Coya Therapeutics Inc stock is traded at $4.80, with a volume of 39,052.
It is up +2.43% in the last 24 hours and down -12.36% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$4.68
Open:
$4.69
24h Volume:
39,052
Relative Volume:
0.15
Market Cap:
$100.23M
Revenue:
-
Net Income/Loss:
$-14.88M
P/E Ratio:
-4.898
EPS:
-0.98
Net Cash Flow:
$-10.29M
1W Performance:
+7.00%
1M Performance:
-12.36%
6M Performance:
-28.13%
1Y Performance:
-18.61%
1-Day Range:
$4.662
$4.86
1-Week Range:
$4.37
$4.86
52-Week Range:
$3.9401
$8.29
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.79 | 97.93M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.10 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.45 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.09 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.12 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
(COYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Coya Therapeutics (COYA): Analyst Maintains 'Buy' Rating with St - GuruFocus
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics advances ALS and FTD clinical trials in 2026 By Investing.com - Investing.com India
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - PharmiWeb.com
Coya Therapeutics Reports Strong Cash Position and Runway - TipRanks
Coya Therapeutics advances ALS and FTD clinical trials in 2026 - Investing.com
Will Coya Therapeutics Inc outperform its industry peers2025 Winners & Losers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Momentum Shift: Is PHAT currently under institutional pressureQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
COYA-302: De-Risked Treg Platform With Compelling FTD Data and ALS Phase 2 Catalyst Supporting Buy Rating - TipRanks
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Can Candel Therapeutics Inc. stock attract ESG capital inflows2025 Momentum Check & Consistent Return Strategy Ideas - ulpravda.ru
Is Coya Therapeutics Inc. stock a safe buy before earnings2025 AllTime Highs & Verified High Yield Trade Plans - Улправда
Is Coya Therapeutics Inc. stock a bargain at current levels2025 Year in Review & High Accuracy Swing Entry Alerts - Улправда
Is Coya Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - Улправда
Is Coya Therapeutics Inc. stock cheap compared to fundamentals2025 Key Lessons & Technical Pattern Based Buy Signals - Улправда
Support Test: How CERo Therapeutics Holdings Inc. stock benefits from global expansionTrade Analysis Report & Weekly Stock Performance Updates - ulpravda.ru
Chardan Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Aug Intraday: How Coya Therapeutics Inc. stock reacts to job market dataJuly 2025 Price Swings & Comprehensive Market Scan Reports - Улправда
Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating - TipRanks
Coya Therapeutics, Inc. Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - marketscreener.com
How Coya Therapeutics Inc. stock reacts to job market data2025 Price Momentum & Entry and Exit Point Strategies - ulpravda.ru
COYA: Analyst Maintains Buy Rating and $15 Target Price | COYA S - GuruFocus
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data - TipRanks
Coya Therapeutics Announces Positive Study Results for FTD Treatment - TradingView — Track All Markets
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Business Wire
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Panic Selling: How Coya Therapeutics Inc stock reacts to job market dataMarket Volume Report & Technical Pattern Recognition Alerts - moha.gov.vn
Coya Therapeutics, Inc.Common Stock (NQ: COYA - FinancialContent
Coya Therapeutics: Clinical Momentum, Extended Cash Runway, and DCF-Derived Upside Support Reiterated Buy and $18 Target - TipRanks
Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral Capital - Defense World
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for CO - PharmiWeb.com
Coya Therapeutics announces FDA acceptance of COYA 302 IND application - TipRanks
US COYA 302 trial in ALS expands to Canada after regulatory nod - ALS News Today
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18 - Investing.com Canada
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - BioSpace
COYA Stock Receives Consistent "Buy" Rating from D. Boral Capita - GuruFocus
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
(COYA) Risk Channels and Responsive Allocation - Stock Traders Daily
Coya announces Health Canada acceptance of COYA 302 clinical trial application - MSN
S P Trends: Will Coya Therapeutics Inc stock pay special dividendsJuly 2025 Price Swings & Long-Term Safe Return Strategies - Bộ Nội Vụ
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Is Coya Therapeutics Stock Built to Withstand More Downside? - Trefis
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics receives clinical trial application acceptance from Health Canada - marketscreener.com
Coya Therapeutics, Inc. Receives Clinical Trial Application Acceptance from Health Canada to Proceed with the COYA302 Alstars Trial for the Treatment of Amyotrophic Lateral Sclerosis - marketscreener.com
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):